Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction With Oligohydramnios.

NCT07462182 is registered in ClinicalTrials.gov with Muhammad Aamir Latif as lead sponsor.

NCT NCT07462182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07462182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction With Oligohydramnios.
Lead sponsor
Muhammad Aamir Latif
Phase
Not applicable
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
September 30, 2026
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intrauterine growth restriction